Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 6/20 | 0.58 |
| ▸ | ITGAV | P06756 | 1/20 | 0.58 |
| ▸ | ITGA4 | P13612 | 5/20 | 0.52 |
| ▸ | ITGB7 | P26010 | 3/20 | 0.47 |
| ▸ | TACR3 | P29371 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 6/20 | 0.41 |
| ▸ | CCKAR | P32238 | 1/20 | 0.40 |
| ▸ | CCKBR | P32239 | 1/20 | 0.40 |
| ▸ | USP28 | Q96RU2 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3316023 | 0.92 | ITGB1 (0.70) | ITGB1ITGAVITGA4ITGB7CCKAR | |
| SCHEMBL3318716 | 0.86 | ITGB1 (0.58) | ITGB1ITGAVITGA4ITGB7 | |
| SCHEMBL27621109 | 0.86 | ITGB1 (0.62) | ITGB1ITGAVITGA4ITGB7CCKAR | |
| SCHEMBL3315049 | 0.86 | ITGB1 (0.62) | ITGB1ITGAVITGA4ITGB7CCKAR | |
| SCHEMBL3314912 | 0.85 | ITGB1 (0.60) | ITGB1ITGAVITGA4ITGB7USP28 | |
| SCHEMBL3315770 | 0.84 | ITGB1 (0.80) | ITGB1ITGAVITGA4ITGB7TACR3 | |
| SCHEMBL3319924 | 0.84 | ITGB1 (0.80) | ITGB1ITGAVITGA4ITGB7TACR3 | |
| SCHEMBL8353596 | 0.84 | ITGB1 (0.80) | ITGB1ITGAVITGA4ITGB7TACR3 | |
| SCHEMBL3316095 | 0.82 | ITGB1 (0.56) | ITGB1ITGAVITGA4ITGB7USP28 | |
| SCHEMBL3313003 | 0.82 | ITGB1 (0.55) | ITGB1ITGAVITGA4ITGB7TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501801-B1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF VLA-4 DEPENDENT DISEASES | UCB PHARMA SA (BE) | 2008-01-23 | — | — | EP | claimed |
| US-20100105681-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | LASSOIE MARIE-AGNES | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105681-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | SCN4A, NECTIN4, VPS4B | ITGB1 274/4885ITGAV 65/4885ITGA4 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.